JW Lifescience Corporation (234080.KS)
KRW 11520.0
(-0.78%)
KRW 11520.0
(-0.78%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 32.09 Billion KRW | 13.93% |
| 2022 | 27.08 Billion KRW | -4.67% |
| 2021 | 28.41 Billion KRW | -27.97% |
| 2020 | 39.45 Billion KRW | 32.61% |
| 2019 | 29.74 Billion KRW | 26.37% |
| 2018 | 23.54 Billion KRW | -0.99% |
| 2017 | 23.77 Billion KRW | 9.92% |
| 2016 | 21.63 Billion KRW | 15.94% |
| 2015 | 18.65 Billion KRW | 27.69% |
| 2014 | 14.61 Billion KRW | 84.41% |
| 2013 | 7.92 Billion KRW | -9.5% |
| 2012 | 8.75 Billion KRW | -7.85% |
| 2011 | 9.49 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 8.38 Billion KRW | -2.57% |
| 2024 Q1 | 8.6 Billion KRW | 7.72% |
| 2023 Q2 | 7.78 Billion KRW | -12.21% |
| 2023 Q3 | 6.23 Billion KRW | -19.9% |
| 2023 Q4 | 7.98 Billion KRW | 28.11% |
| 2023 FY | 30.86 Billion KRW | 13.93% |
| 2023 Q1 | 8.86 Billion KRW | 12.01% |
| 2022 Q4 | 7.91 Billion KRW | 536.6% |
| 2022 Q1 | 6.83 Billion KRW | 2.95% |
| 2022 Q2 | 7.04 Billion KRW | 3.02% |
| 2022 Q3 | 1.24 Billion KRW | -82.35% |
| 2022 FY | 27.08 Billion KRW | -4.67% |
| 2021 Q2 | 7.45 Billion KRW | -10.03% |
| 2021 FY | 28.41 Billion KRW | -27.97% |
| 2021 Q4 | 6.64 Billion KRW | 10.23% |
| 2021 Q1 | 8.29 Billion KRW | -20.32% |
| 2021 Q3 | 6.02 Billion KRW | -19.24% |
| 2020 Q3 | 9.5 Billion KRW | -7.73% |
| 2020 FY | 39.45 Billion KRW | 32.61% |
| 2020 Q4 | 10.4 Billion KRW | 9.43% |
| 2020 Q1 | 9.22 Billion KRW | 30.31% |
| 2020 Q2 | 10.3 Billion KRW | 11.67% |
| 2019 Q3 | 7.09 Billion KRW | -7.16% |
| 2019 FY | 29.74 Billion KRW | 26.37% |
| 2019 Q4 | 7.08 Billion KRW | -0.25% |
| 2019 Q2 | 7.64 Billion KRW | -3.43% |
| 2019 Q1 | 7.91 Billion KRW | 21.18% |
| 2018 Q4 | 6.53 Billion KRW | -9.07% |
| 2018 Q3 | 7.18 Billion KRW | 25.33% |
| 2018 Q1 | 4.08 Billion KRW | -12.68% |
| 2018 FY | 23.54 Billion KRW | -0.99% |
| 2018 Q2 | 5.73 Billion KRW | 40.38% |
| 2017 Q4 | 4.67 Billion KRW | -26.21% |
| 2017 Q3 | 6.34 Billion KRW | 1.53% |
| 2017 FY | 23.77 Billion KRW | 9.92% |
| 2017 Q2 | 6.24 Billion KRW | -4.13% |
| 2017 Q1 | 6.51 Billion KRW | 49.3% |
| 2016 Q2 | 5.41 Billion KRW | -15.76% |
| 2016 Q4 | 4.36 Billion KRW | -19.42% |
| 2016 Q3 | 5.41 Billion KRW | -0.11% |
| 2016 FY | 21.63 Billion KRW | 15.94% |
| 2016 Q1 | 6.43 Billion KRW | 42.19% |
| 2015 Q4 | 4.52 Billion KRW | 8.26% |
| 2015 Q3 | 4.17 Billion KRW | -24.31% |
| 2015 FY | 18.65 Billion KRW | 27.69% |
| 2015 Q2 | 5.52 Billion KRW | 0.0% |
| 2014 FY | 14.61 Billion KRW | 84.41% |
| 2013 FY | 7.92 Billion KRW | -9.5% |
| 2012 FY | 8.75 Billion KRW | -7.85% |
| 2011 FY | 9.49 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -8703.35% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 58.259% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 140.335% |
| HANDOK Inc. | 12.57 Billion KRW | -155.123% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 1713.332% |
| Yuhan Corporation | 74.56 Billion KRW | 56.96% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -187.083% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 277.866% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 85.73% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -950.093% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -123.627% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -5280.84% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -3229.802% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | -18.719% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -8703.35% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 513.76% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -695.598% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 145.878% |
| JW Holdings Corporation | 143.66 Billion KRW | 77.662% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 160.077% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 86.986% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 68.006% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 167.714% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -363.286% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -395.926% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -267.542% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -8703.35% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 34.195% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 75.945% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 68.006% |
| Yuhan Corporation | 74.56 Billion KRW | 56.96% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | -53.4% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -929.433% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 25.36% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 68.006% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | -56.663% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 41.598% |
| CKD Bio Corp. | -20.15 Billion KRW | 259.243% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 0.438% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | -26.833% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 1.333% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 167.714% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 3.184% |
| Boryung Corporation | 68.26 Billion KRW | 52.991% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 185.585% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -123.627% |